Ignis Therapeutics (Suzhou) Limited

1 clinical trials · Sponsor

Record	Firm	Date
A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA) (NCT06103825)	Ignis Therapeutics (Suzhou) Limited	2023-08-01

Every clearance here is in the API, with alerts when new ones post.